Fiche centre
Centre Hospitalier de l'Universite de Montreal
Montreal — Canada
Essais liés8clinical trials
VilleMontreallocalisation
PaysCanadalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06051123
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Prophylactic defect closure | Cancer | Non applicable | NCT06807073 | Closure-RCT — Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps | RECRUITING |
| Emapalumab | Lupus | Phase 3 | NCT05001737 | EMERALD — Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | COMPLETED |
| PF-06821497 | Cancer | Phase 3 | NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | RECRUITING |
| Post-operative radiotherapy | Cancer | Phase 2 | NCT06878274 | RESCUE — Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC | RECRUITING |
| Radiotherapy | Cancer | À vérifier | NCT04115267 | Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies | RECRUITING |
| SBRT | Cancer | Phase 1/2 | NCT03283605 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | COMPLETED |
| Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients | Sclérose latérale amyotrophique | Non applicable | NCT06051123 | Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients | RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |